2m 2m 2m 2m 2m 2m 2m
- $20.7MMarket Cap
- -53.38%1-Year Change
- Software - ApplicationIndustry
FIREFLY NEURO (AIFF)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 7
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Firefly Neuroscience researchers have developed a new method to accurately differentiate between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia in Alzheimer's patients using a combination of EEG/ERP and volumetric MRI data.
06/20/2025, 7:45 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury. It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.
Key Executives
- Greg Lipschitz
- David DeCaprio
- Gil Issachar
- Paul Krzywicki
Current Ownership Distribution
- Other7.0M (44.81%)
- Institutions4.1M (26.23%)
- Insiders2.7M (17.05%)
- Mutual Funds1.9M (11.91%)